Meeting
2013 ASCO Annual Meeting
A phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.
Authors
Talia Golan
Sheba Medical Center, Tel HaShomer, Israel
Talia Golan , Ayala Hubert , Amotz Shemi , Amiel Segal , Alan Dancour , Elina Zorde Khvalevsky , Eliel Ben-David , Stephen Raskin , Yuri Goldes , Yael Inbar , Maor Lahav , Avi Domb , Eithan Galun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT01188785
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4037)
DOI
10.1200/jco.2013.31.15_suppl.4037
Abstract #
4037
Poster Bd #
15G
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NeoOPTIMIZE: An open-label, phase II trial and biomarker discovery platform to assess the efficacy of adaptive switching of modified FOLFIRINOX (mFFX) or gemcitabine/nab-paclitaxel (GA) as a neoadjuvant strategy for patients with resectable/borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).
First Author: Charles D. Lopez
Poster
2021 ASCO Annual Meeting
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
First Author: Nai-Jung Chiang
Poster
2014 Gastrointestinal Cancers Symposium
Novel Kras-directed therapy in combination with chemotherapy for locally advanced pancreatic adenocarcinoma.
First Author: Talia Golan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FOLFIRINOX plus high intensity focused ultrasound for locally advanced/borderline resectable pancreatic ductal adenocarcinoma: A prospective single arm phase II trial.
First Author: Dong Ho Lee